Antifungal Drugs Market Size, Share, Revenue, Scope, Top Key Players, Covid-19 Analysis Report Forecast, 2020-2023

04/nov/2020 11:37:28 Automotive Market Research Reports Contatta l'autore

Questo comunicato è stato pubblicato più di 3 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

The global antifungal drugs market accounted for $14.23 billion in 2017 and is anticipated to reach $17.72 billion by 2023, growing at a CAGR of 3.7% during the forecast period.

Antifungal drugs are medications that selectively eliminate fungal infections from the host. These fungal agents multiply by spreading spores that subsequently lead to infection on skin, hairs, vagina, and other body parts. The fungal infection causes candidiasis, fungal pneumonia, mucormycosis, and other diseases. The antifungal drugs market is continuously growing and evolving owing to robust developmental efforts made by researchers and market players in the field.

Key market players

The key players analyzed in the report include Pfizer Inc., Sanofi S.A., Gilead Sciences, Inc., Merck & Co., Inc., Novartis International AG, Abbott Laboratories, Bayer AG, Scynexis Inc., Enzon Pharmaceuticals, Inc., and GlaxoSmithKline Plc. They have adopted different strategies including collaborations, joint ventures, partnerships, expansions, mergers & acquisitions, and others to gain a strong position in the industry.

Based on therapeutic indication, Candidiasis segment held more than one-third of the total market share in 2017 and will maintain its dominance throughout the forecast period. However, the Dermatophytosis segment is estimated to register the highest growth rate with a CAGR of 4.1% from 2017 to 2023.

Azoles projected to be the primary drug type in the near future

Based on drug type, azoles is projected to be the largest and fastest growing segment throughout the forecast period, growing at a CAGR of 3.9% to occupy more than one-third of the global market by 2023. Azoles play an active role in the treatment of many fungal infections and the newer versions have evolved to be the first line of defense against myriad fungal infections such as aspergillosis.

Asia-Pacific to grow at the fastest rate through 2023

Asia-Pacific is expected to register the highest growth rate of 4.5% CAGR throughout the forecast period, owing to the presence of countries with a high populace base, such as India and China, where the antifungal drug usage rate is on a rise due to the growing awareness about fungal infections among the common people and high prevalence of diseases.

Read More:

blog comments powered by Disqus è un servizio offerto da Factotum Srl